Jim Cramer: This Financial Stock Is 'One Of The Most Consistent, Great Companies'
Portfolio Pulse from Avi Kapoor
Jim Cramer recommends buying Vertex Pharmaceuticals, CME Group, and T. Rowe Price Group, while advising against selling Micron Technology. Vertex's price target was slightly lowered by Oppenheimer. CME reported strong earnings, and Micron announced board changes.
October 31, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CME Group is recommended as a strong buy by Jim Cramer. The company reported earnings and sales that beat analyst estimates.
Cramer's strong buy recommendation and CME's earnings beat suggest a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Jim Cramer recommends buying T. Rowe Price Group. The company recently appointed Ben Riley as Head of Insurance.
Cramer's recommendation and recent leadership changes could positively influence TROW's stock in the short term.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Jim Cramer recommends buying Vertex Pharmaceuticals. Oppenheimer maintained an Outperform rating but slightly lowered the price target from $550 to $540.
Cramer's positive recommendation and the maintained Outperform rating by Oppenheimer, despite a slight price target reduction, suggest a positive short-term impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Jim Cramer advises against selling Micron Technology. The company announced board changes, with the current Board Chair set to retire in 2025.
Cramer's advice against selling and the announcement of board changes may stabilize MU's stock, but the recent price drop suggests a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 75